ITGB2 and cancer: Although not currently undergoing trials in cancer therapy, LFA-1 has been the object of intense study in a number of clinical trials [12], with different modes of application including antibody therapy (Odulimomab), small molecules (SAR1118) and siRNA approaches [13].